← Back to all trials
Completed
NCT07600905
Avatrombopag Versus Standard Care for Low Platelet Counts After Liver Transplant
Conditions: Postoperative Complication, Severe Thrombocytopenia, Liver Transplantation (LT)
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 245
Sponsor: Shanghai Zhongshan Hospital
Location: Zhongshan Hospital, Fudan University Shanghai Shanghai Municipality
Summary
This retrospective cohort study evaluated adult recipients of liver transplantation (LT) who developed severe post-transplantation thrombocytopenia, defined as a platelet count below 30 x 10\^9/L within 7 days after LT, at a single centre in China between November 2019 and August 2025. Participants received either avatrombopag or standard care. Avatrombopag was given orally at 40 mg once daily for 5 days, started when the postoperative platelet count fell below 30 x 10\^9/L. Standard care included recombinant human thrombopoietin. The primary objective was to compare the rate of platelet count recovery between the two groups. Secondary objectives were to compare blood product use and 30-day complications. A total of 245 eligible participants were identified; 70 received avatrombopag and 175 received standard care. One-to-two propensity score matching produced an analysis cohort of 70 avatrombopag recipients and 140 matched controls. The hypothesis was that avatrombopag would accelerate platelet recovery and reduce transfusion requirements without increasing thrombosis.
Eligibility Criteria
Inclusion Criteria: (1) were aged 18 years or older; and (2) developed severe post transplantation thrombocytopenia (SPT), defined as a nadir platelet count below 30×10⁹/L within the first 7 days after LT.
Exclusion criteria: (1) use of avatrombopag within 4 weeks before LT; (2) second or subsequent LT; (3) death from surgical complications within 7 days after LT; (4) incomplete platelet measurement records; and (5) age younger than 18 years.
Source: ClinicalTrials.gov (NCT07600905). StuddyBuddy aggregates publicly available trial information.